Scientists identify new drug that could treat COVID-19 pneumonia: Lancet

The study involved 54 patients receiving 'usual care' and 57 patients given usual care as well as a single intravenous dose of 150mg of namilumab.
A research published in the Lancet journal identified a new drug that could help treat Covid-19 pneumonia.(Sonu Mehta/HT PHOTO)
A research published in the Lancet journal identified a new drug that could help treat Covid-19 pneumonia.(Sonu Mehta/HT PHOTO)
Published on Dec 18, 2021 11:35 AM IST
Copy Link
PTI | , London

A newly identified drug may be used to effectively treat some patients hospitalised with COVID-19 pneumonia, according to a study published in The Lancet Respiratory Medicine journal.

The team, including researchers from the University of Birmingham and the University of Oxford, UK, tested namilumab -- an antibody already in late-stage trials to treat rheumatoid arthritis -- in patients hospitalised with COVID-19 pneumonia.

The patients were receiving 'usual' care, as well as having high levels in their blood of a marker of inflammation known as C reactive protein (CRP).

CRP levels rise when there is inflammation in the body, and elevated levels of CRP have been found to be a potential early marker to predict risk for severity of COVID-19, the researchers said.

"Our research has provided important proof-of-concept evidence that namilumab reduces inflammation in hospitalised patients with COVID-19 pneumonia," said Ben Fisher, co-chief investigator of the trial at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust (UHB).

"However, our sample size is too small for a definitive assessment of clinical outcomes and further studies are required for this, as well as to understand better the population that may benefit most,” Fisher said.

Namilumab targets a ‘cytokine’ which is naturally secreted by immune cells in the body, but in uncontrolled levels is believed to be a key driver of the excessive and dangerous lung inflammation seen in COVID-19 patients.

The trial carried out between June 2020 and February 2021 involved patients aged over 16 with COVID-19 pneumonia either being treated on a ward or Intensive Care Unit (ICU) at nine hospitals across the UK.

The study involved 54 patients receiving 'usual care' -- treatment with steroids and oxygen or ventilation -- and 57 patients given usual care as well as a single intravenous dose of 150mg of namilumab.

As well as COVID-19 pneumonia, all study participants had CRP levels greater than 40mg/l.

The researchers compared the probability of the reduction of levels of CRP in patients.

Compared to usual care alone, the researchers found that there was a 97 per cent probability of CRP being reduced over time in those given namilumab when compared with usual care alone.

The patients were monitored, and after 28 days the study also showed there were fewer deaths and more discharges from hospital or ICU in those who had been given namilumab compared to those receiving usual care alone.

By day 28, 78 per cent of the patients receiving namilumab were discharged from hospital or ICU, compared to 61 per cent given usual care.

In the namilumab group, 11 per cent were still in hospital by day 28, compared to 20 per cent in the usual care group, according to the researchers. Of those in the namilumab group, 11 per cent patients died compared to 19 per cent who died in the usual care group by day 28, they said.

The team calculated the differences between the two groups in overall probability of those being discharged from ICU or a ward at 28 days. Of those on a ward, the probability of discharge at day 28 was 64 per cent in the usual care group, compared to 77 per cent in the namilumab cohort.

Of those in ICU, probability of discharge at day 28 was 47 per cent in the usual care group, compared to 66 per cent in the namilumab cohort, according to the study.

The researchers noted that the study results may not generalise to hospitalised patients without evidence of pneumonia or raised CRP or patients not requiring hospitalisation.

It is important, therefore, that namilumab is now prioritised for further COVID-19 research in a much larger phase 3 clinical trial, they added.

SHARE THIS ARTICLE ON
Close Story
QUICKREADS

Less time to read?

Try Quickreads

  • As 'partygate' grew, Johnson became the first UK PM found to have broken the law while in office.

    ‘Morning everyone....oh’: Twitter floods with memes as UK PM clings to power

    British prime minister Boris Johnson - holding on to power precariously after multiple members oJohnson'sis cabinet resigned over the past few days - has become the subject of memes among the online community. A slew of these memes have surfaced on Twitter, encapsulating the current political crisis in Britain as Johnson stares at the strong possibility of being removed as Conservative Party leader and PM.

  • Residential and commercial skyscrapers on the skyline of Abu Dhabi, UAE. (Bloomberg)

    Beijing-based AIIB opens Abu Dhabi office in face of China’s zero-Covid policy

    The China-backed Asian Infrastructure Investment Bank on Thursday announced the opening of its first office outside its Beijing headquarter, in what appears to be an effort to negotiate China's Covid-19-related policies including restrictions on international travel and strict quarantine requirements for returnees. “The AIIB Board of Directors has approved the establishment of an Interim Operational Hub (the Hub), the bank's first overseas office,” the multilateral lender said in a statement on Thursday.

  • Sonia Anand, professor at McMaster University and principal investigator for the study. (McMaster University)

    South Asians may have suffered more than general public in Covid-19: Canadian study

    South Asian communities may have suffered more during the Covid-19 pandemic than the general population, according to an indicative study published in Canada. Researchers from McMaster University in Hamilton, Ontario, “found the Regional Municipality of Peel, home to a large South Asian Canadian community, emerged as a Covid-19 hotspot before the local rollout of vaccines starting in April 2021”. The city of Brampton was the “epicentre”.

  • Representative image: Chicecream said Wednesday that its products were in line with national food safety regulations.

    Chinese ice cream brand under fire for products that don't melt

    A Chinese brand once dubbed the "Hermes of ice cream" has come under fire after internet users said some of its products do not melt -- even when baked with a blowtorch. The most expensive offering of Chicecream -- called "Zhong Xue Gao" in Chinese -- costs 66 yuan ($10). Chicecream has promoted itself as a Chinese alternative to Western brands such as Magnum and Haagen-Dazs, using supposedly natural ingredients and locally-inspired product designs.

  • Ukrainian soldiers ride an armoured vehicle on the main road to Lysychansk in Ukraine�s eastern region of Donbas on June 26, 2022.

    Russia pounds rebel-claimed region, Ukraine pushes back

    Russia redoubled its push for Ukraine's eastern Donbas region Wednesday, with the Ukrainian military claiming to have repelled some advances and both sides reporting casualties. The Ukrainian armed forces General Staff said troops stopped enemy units advancing towards Sloviansk, a city in Donetsk, one of two provinces in the Donbas whose capture is among Moscow's main goals. “Every crime will be punished,” he wrote on social media.

SHARE
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, July 07, 2022